GlassScriptPhysician profile
Molly M Brown
NPI 1750158473
$1,358.62
in general payments reported to CMS, 2019-2025
21 companies · $652 in 2025
The $652 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $27.77 · 2024: $679 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,359.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,358.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $516.73 | 2023-2025 | |
| Lilly USA, LLC | $113.39 | 2024-2025 | Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $113.33 | 2024-2025 | Trintellix |
| Novo Nordisk INC | $95.81 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Janssen Pharmaceuticals, INC | $51.68 | 2024-2025 | Spravato, Invega Sustenna, Xarelto |
| Astrazeneca Pharmaceuticals LP | $50.78 | 2024-2025 | Airsupra |
| Mayne Pharma Commercial LLC | $47.31 | 2024-2025 | |
| Amgen INC. | $46.60 | 2024 | Evenity, Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $41.04 | 2024-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.06 | 2025 | Caplyta |
| Azurity Pharmaceuticals, INC. | $33.12 | 2024 | Edarbi |
| Pfizer INC. | $30.84 | 2025 | |
| Merck Sharp & Dohme LLC | $30.21 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.81 | 2024 | |
| Corium, LLC | $25.88 | 2024 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $19.73 | 2024 | Crysvita |
| Boston Scientific Corporation | $16.88 | 2024 | Watchman Flx |
| Axsome Therapeutics, INC. | $16.65 | 2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.61 | 2024 | Xifaxan |
| Xeris Pharmaceuticals, INC. | $14.95 | 2024 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $14.21 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.